{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002291","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.334210+00:00","generated_at":"2026-06-27T03:25:11.064116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M","bullets":["Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).","Q4 net loss $43.1M ($0.27/sh) vs. $66.8M ($0.42/sh) in Q4 2020; full-year loss $167.9M ($1.05/sh).","Resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis; Phase 3 Lavender trial of trofinetide in Rett syndrome positive.","FY2022 guidance: NUPLAZID net sales $510-560M; R&D expense $355-375M; SG&A $360-380M.","Cash and investments $520.7M at Dec 31, 2021, down from $632.0M a year earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002291","json":"https://secwatch.observer/filing/0000950170-22-002291.json","markdown":"https://secwatch.observer/filing/0000950170-22-002291.md","text":"https://secwatch.observer/filing/0000950170-22-002291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/0000950170-22-002291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022002291/acad-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:25:11.064116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}